70758-92-8 Usage
Type of medication
Chemotherapy drug
Purpose
Treats certain types of brain tumors, such as glioblastoma multiforme and anaplastic astrocytoma
Mechanism of action
Disrupts the growth and spread of cancer cells in the body
Prodrug
Inactive until metabolized in the body to its active form, 5-fluorouracil
Active form
5-fluorouracil
Function of active form
Inhibits DNA replication, causing cancer cell death
Administration
Typically taken orally
Treatment approach
Often used in combination with radiation therapy for more effective treatment
Importance
Potent and crucial drug in the treatment of aggressive and difficult-to-treat brain tumors, providing hope for patients with these conditions
Check Digit Verification of cas no
The CAS Registry Mumber 70758-92-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,0,7,5 and 8 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 70758-92:
(7*7)+(6*0)+(5*7)+(4*5)+(3*8)+(2*9)+(1*2)=148
148 % 10 = 8
So 70758-92-8 is a valid CAS Registry Number.
InChI:InChI=1/C8H9FN2O3S/c9-5-4-11(8(13)10-7(5)12)6-2-1-3-15(6)14/h4,6H,1-3H2,(H,10,12,13)
70758-92-8Relevant articles and documents
Synthesis and Antitumor Activity of a Series of Ftorafur Analogues: The Effect of Varying Electronegativity at the 1'-Position
Holshouser, Mark H.,Shipp, Annette M.,Ferguson, Paul W.
, p. 242 - 245 (2007/10/02)
To test the effect of changes in electronegativity within the alicyclic N-1 substituent of substituted 5-fluorouracil analogues on cytotoxic activity, a series of derivatives of ftorafur, 1-(2'-tetrahydrofuranyl)-5-fluorouracil, was synthesized and tested for antitumor activity in the P388 lymphocytic leukemia screen and cytotoxic activity in the L1210 cell culture screen.Two compounds of N-1 substituent with high electronegativity, the 2'-tetrahydrothiophene 1'-oxide and the 2'-tetrahydrothiophene 1',1'-dioxide derivatives, demonstrated the highest in vitro L1210 cell inhibition (84.5percent and 92.0percent, respectively).Furthermore, against P388 lymphocytic leukemia in vivo, the 2'-tetrahydrothiophene 1'-oxide derivative showed significant activity (T/C = 143).Other compounds of similar or lower electronegativity within the N-1 cyclic substituent were inactive against P388 lymphocytic leukemia and less active against L1210 cells.
